These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11821722)

  • 41. [The medicine of the month. Losartan (Cozaar)].
    Scheen AJ
    Rev Med Liege; 1997 May; 52(5):367-9. PubMed ID: 9273640
    [No Abstract]   [Full Text] [Related]  

  • 42. Irbesartan achieves consistent and effective use over 1 year.
    Cardiovasc J S Afr; 2001; 12(2):126. PubMed ID: 11474701
    [No Abstract]   [Full Text] [Related]  

  • 43. [Enalapril and irbesartan in treatment of patients with arterial hypertension].
    Tashchuk VK; Ilashchuk TO
    Lik Sprava; 2002; (3-4):114-6. PubMed ID: 12145874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irbesartan for hypertension.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
    Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin receptor blockers in essential hypertension.
    Brown MJ
    Lancet; 1993 Dec; 342(8884):1374-5. PubMed ID: 7901674
    [No Abstract]   [Full Text] [Related]  

  • 47. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
    de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
    Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Losartan vs. amlodipine treatment in elderly oncologic hypertensive patients: a randomized clinical trial.
    Motta M; Russo C; Vacante M; Liardo RL; Reitano F; Cammalleri L; Costanzo M; Benfatto G; Frazzetto P; Mondati E; Malaguarnera M; Pennisi G
    Arch Gerontol Geriatr; 2011; 53(1):60-3. PubMed ID: 20569998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AT1-receptor antagonists for the treatment of chronic heart failure.
    Baan J
    Cardiovasc Res; 1999 Jan; 41(1):14-5. PubMed ID: 10325947
    [No Abstract]   [Full Text] [Related]  

  • 50. Losartan: a new antihypertensive drug.
    Dubois M; Wilson TW
    Can Nurse; 1997 Jun; 93(6):31-4. PubMed ID: 9233121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
    Pouleur HG
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.
    Milionis HJ; Nikas S; Elisaf MS
    Am J Cardiol; 2001 Nov; 88(9):1084. PubMed ID: 11704020
    [No Abstract]   [Full Text] [Related]  

  • 54. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
    Gansevoort RT; de Zeeuw D; Shahinfar S; Redfield A; de Jong PE
    J Hypertens Suppl; 1994 Jul; 12(2):S37-42. PubMed ID: 7965264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The pleiotropic effects of losartan--the importance of decreasing uric acid level].
    Csiky B; Markó L; Mohás M; Cseh J; Mikolás E; Szíjártó I; Wittmann I
    Lege Artis Med; 2008 Oct; 18(10):663-6. PubMed ID: 19227608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cost-effectiveness of irbesartan for hypertension.
    Borghi C; Urso R; Cicero AF
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):199-207. PubMed ID: 25703678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):242-4. PubMed ID: 15816499
    [No Abstract]   [Full Text] [Related]  

  • 59. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 60. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.